Clinical supervision of chronic atrophic gastritis
https://doi.org/10.31146/1682-8658-ecg-211-3-148-155
Abstract
Patients with chronic gastritis (CG) with the development of atrophy of the gastric mucosa are at an increased risk of developing gastric cancer (GC). In the management of such patients, the development of high-grade dysplasia and invasive gastric cancer should be defined as adverse outcomes that must be prevented. To this end, patients with a diagnosis of «Chronic atrophic fundic/multifocal gastritis» are subject to dynamic dispensary observation to assess the achievement of target indicators, take into account information about changes in the diagnosis and concomitant diseases, emerging complications, as well as to enter data on ongoing therapeutic and preventive measures. This article presents the main aspects of prevention and dispensary monitoring of patients with an increased risk of gastric cancer.
About the Authors
M. A. Livzan
Omsk State Medical University
Russian Federation
Russian Federation
O. V. Gaus
Omsk State Medical University
Russian Federation
Russian Federation
M. A. Lisovskiy
Omsk State Medical University
Russian Federation
Russian Federation
S. I. Mozgovoi
Omsk State Medical University
Russian Federation
Russian Federation
V. A. Rubtsov
Omsk State Medical University
Russian Federation
Russian Federation
M. N. Parygina
Omsk State Medical University
Russian Federation
Russian Federation
References
1. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52(24): 6735-6740.
2. Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ. 2004;(157): 301-310.
3. Graham D. Y., Rugge M., Genta R. M. Diagnosis: gastric intestinal metaplasia - what to do next? Curr Opin Gastroenterol. 2019;35(6): 535-543. doi: 10.1097/MOG.0000000000000576.
4. Kato I., Tominaga S., Ito Y., et al. A prospective study of atrophic gastritis and stomach cancer risk. Jpn J Cancer Res. 1992;83(11): 1137-1142. doi: 10.1111/j.1349-7006.1992.tb02736.x.
5. Mera R. M., Bravo L. E., Camargo M. C., et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut. 2018;67(7): 1239-1246. doi: 10.1136/gutjnl-2016-311685.
6. Yue H., Shan L., Bin L. The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2018;21(4): 579-587. doi: 10.1007/s10120-018-0812-3.
7. Shichijo S., Hirata Y, Niikura R, et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest Endosc. 2016;84(4):618-624. doi: 10.1016/j.gie.2016.03.791.
8. Shah S. C., Peek R. M. Jr. Chemoprevention Against Gastric Cancer. Gastrointest Endosc Clin N Am. 2021;31(3): 519-542. doi: 10.1016/j.giec.2021.03.006.
9. Livzan M. A., Gaus O. V., Mozgovoi S. I., Bordin D. S. Chronic Autoimmune Gastritis: Modern Diagnostic Principles. Diagnostics (Basel). 2021;11(11): 2113. doi: 10.3390/diagnostics11112113.
10. Ivashkin V. T., Maev I. V., Lapina T. L. et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4): 70-99. (In Russ.) doi: 10.22416/1382-4376-2021-31-4-70-99.@@ Ивашкин В. Т., Маев И. В., Лапина Т. Л. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации «Эндоскопическое общество РЭНДО» по диагностике и лечению гастрита, дуоденита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(4): 70-99. (In Russ.) doi: 10.22416/1382-4376-2021-31-4-70-99.
11. Alekseyenko S.A., Bagdasaryan A. A., Bakulin I. G. et al. Brief algorithms for managing patients at the stage of providing primary health care. A guide for general practitioners. Ed. by O. M. Drapkinа. Moscow: Vidoks; 2019. 20 р. (In Russ.)@@ Алексеенко С. А., Багдасарян А. А., Бакулин И. Г., и др. Краткие алгоритмы ведения пациентов на этапе оказания первичной медико-санитарной помощи. Пособие для врачей-терапевтов / Под ред. О. М. Драпкиной. - М.: Видокс, 2019. - 20 с. (In Russ.)
12. Aruin L.I., Kononov A. V., Mozgovoy S. I.International classification of chronic gastritis: what to accept or revisit. Pathology Archive. 2009;71(4): 11-18. (In Russ.)@@ Аруин Л. И., Кононов А. В., Мозговой С. И. Международная классификация хронического гастрита: что следует принять и что вызывает сомнения. Архив патологии. 2009;71(4): 11-8. (In Russ.)
13. Kumar S., Metz D. C., Ellenberg S. et al. Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study. Gastroenterology. 2020;158(3): 527-536.e7. doi: 10.1053/j.gastro.2019.10.019.
14. Tsuda M., Asaka M., Kato M. et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22(5): e12415. doi: 10.1111/hel.12415.
15. Lee Y. C., Chiang T. H., Chou C. K., et al. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016;150(5): 1113-1124.e5. doi: 10.1053/j.gastro.2016.01.028.
16. Livzan M. A., Kononov A. V., Mozgovoi S. I. Ex-helicobacter gastritis: neologism or clinical reality? Experimental and Clinical Gastroenterology. 2004;5: 55-60. (in Russ.)@@ Ливзан М. А., Кононов А. В., Мозговой С. И. Экс-хеликобактерный гастрит: неологизм или клиническая реальность? Экспериментальная и клиническая гастроэнтерология. 2004;5: 55-60.
17. Kononov M.A., Mozgovoy S. I. Posteradication period of chronic gastritis associated with Helicobacter pylori infection. Consilium Medicum. 2008;10(8): 15-20. (In Russ.)@@ Кононов М. А., Мозговой С. И. Постэрадикационный период хронического гастрита, ассоциированного с инфекцией Helicobacter pylori. Consilium Medicum. 2008;10(8): 15-20. (In Russ.)
18. Shimada M., Ina K., Kyokane K. et al. Upregulation of mucosal soluble fas ligand and interferon-gamma may be involved in ulcerogenesis in patients with Helicobacter pylori-positive gastric ulcer. Scand J Gastroenterol. 2002;37(5): 501-511. doi: 10.1080/00365520252903026.
19. Osawa H., Kita H., Ohnishi H. et al. Histamine-2 receptor expression in gastric mucosa before and after Helicobacter pylori cure. Aliment Pharmacol Ther. 2005;21 Suppl 2: 92-98. doi: 10.1111/j.1365-2036.2005.02481.x
20. Cheung K. S., Leung W. K. Risk of gastric cancer development after eradication of Helicobacter pylori. World J Gastrointest Oncol. 2018;10(5): 115-123. doi: 10.4251/wjgo.v10.i5.115.
21. Correa P., Piazuelo M. B., Camargo M. C. The future of gastric cancer prevention. Gastric Cancer. 2004;7(1): 9-16. doi: 10.1007/s10120-003-0265-0.
22. Toh B. H. Diagnosis and classification of autoimmune gastritis. Autoimmun Rev. 2014;13(4-5): 459-462. doi: 10.1016/j.autrev.2014.01.048.
23. Coati I, Fassan M, Farinati F, Graham DY, Genta RM, Rugge M. Autoimmune gastritis: Pathologist’s viewpoint. World J Gastroenterol. 2015;21(42):12179-12189. doi: 10.3748/wjg.v21.i42.12179.
24. Lijinsky W. N-Nitroso compounds in the diet. Mutat Res. 1999;443(1-2): 129-138. doi: 10.1016/s1383-5742(99)00015-0.
25. Poplawski T., Chojnacki C., Czubatka A. et al. Helicobacter pylori infection and antioxidants can modulate the genotoxic effects of heterocyclic amines in gastric mucosa cells. Mol Biol Rep. 2013;40(8): 5205-5212. doi: 10.1007/s11033-013-2622-3.
26. Ohgaki H., Takayama S., Sugimura T. Carcinogenicities of heterocyclic amines in cooked food. Mutat Res. 1991;259(3-4): 399-410. doi: 10.1016/0165-1218(91) 90130-e.
27. Tsugane S. Salt, salted food intake, and risk of gastric cancer: epidemiologic evidence. Cancer Sci. 2005;96(1): 1-6. doi: 10.1111/j.1349-7006.2005.00006.x.
28. Poorolajal J., Moradi L., Mohammadi Y. et al. Risk factors for stomach cancer: a systematic review and meta-analysis. Epidemiol Health. 2020;42: e2020004. doi: 10.4178/epih.e2020004.
29. D’Elia L., Rossi G., Ippolito R. et al. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. Clin Nutr. 2012;31(4): 489-498. doi: 10.1016/j.clnu.2012.01.003.
30. Wu B., Yang D., Yang S., Zhang G. Dietary Salt Intake and Gastric Cancer Risk: A Systematic Review and Meta-Analysis. Front Nutr. 2021;8: 801228. doi: 10.3389/fnut.2021.801228.
31. Toh J. W.T., Wilson R. B. Pathways of Gastric Carcinogenesis, Helicobacter pylori Virulence and Interactions with Antioxidant Systems, Vitamin C and Phytochemicals.Int J Mol Sci. 2020;21(17): 6451. doi: 10.3390/ijms21176451.
32. Kong P., Cai Q., Geng Q. et al. Vitamin intake reduce the risk of gastric cancer: meta-analysis and systematic review of randomized and observational studies. PLoS One. 2014;9(12): e116060. doi: 10.1371/journal.pone.0116060.
33. Taylor P. R. Prevention of gastric cancer: a miss. J Natl Cancer Inst. 2007;99(2): 101-103. doi: 10.1093/jnci/djk026.
34. Bjelakovic G., Nikolova D., Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm? PLoS One. 2013;8(9): e74558. doi: 10.1371/journal.pone.0074558.
35. Livzan M. A., Gaus O. V., Mozgovoi S. I. Chronic atrophic gastritis: patient management.Russian Medical Inquiry. 2021;5(6):427-432. (in Russ.) doi: 10.32364/2587-6821-2021-5-6-427-432.@@ Ливзан М. А., Гаус О. В., Мозговой С. И. Хронический атрофический гастрит: тактика курации пациента. РМЖ. Медицинское обозрение. 2021;5(6): 427-432. doi: 10.32364/2587-6821-2021-5-6-427-432.
36. Ivashkin V. T., Mayev I. V., Lapina T. L. et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Ross z gastroenterol gepatol koloproktol. 2018;28(1): 55-70. (in Russ.) doi: 10.22416/1382-4376-2018-28-1-55-70.@@ Ивашкин В. Т., Маев И. В., Лапина Т. Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(1): 55-70. doi: 10.22416/1382-4376-2018-28-1-55-70.
37. Bordin D.S Livzan M. A. The consensus Maastricht VI is published: what’s new? Effective pharmacotherapy. 2022; 18 (22): 72-84. (In Russ.) doi: 10.33978/2307-3586-2022-18-22-72-84.@@ Бордин Д. С., Ливзан М. А. Консенсус Маастрихт VI опубликован: что нового? Эффективная фармакотерапия. 2022; 18 (22): 72-84. doi: 10.33978/2307-3586-2022-18-22-72-84.
38. Livzan M.A., Mozgovoj S. I., Kononov A. V. Gastritis after eradication of Helicobacter pylori - simple traces or serious consequences? Lechashchij vrach. 2011;7:7 (In Russ.)@@ Ливзан М. А., Мозговой С. И., Кононов А. В. Гастрит после эрадикации Helicobacter pylori - простые следы или серьезные последствия? Лечащий врач. 2011;7:7.
39. Kamada T., Sato M., Tokutomi T., et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015;2015: 865146. doi: 10.1155/2015/865146.
40. Seo G. H., Lee H. Chemopreventive Effect of Rebamipide against Gastric Cancer in Patients who undergo Endoscopic Resection for Early Gastric Neoplasms: A Nationwide Claims Study. Digestion. 2019;100(4): 221-228. doi: 10.1159/000495288.
41. Pimentel-Nunes P., Libânio D., Marcos-Pinto R. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4): 365-388. doi: 10.1055/a-0859-1883.
42. Lenti M. V., Rugge M., Lahner E. et al. Autoimmune gastritis. Nat Rev Dis Primers. 2020;6(1): 56. doi: 10.1038/s41572-020-0187-8.
43. Order of the Ministry of Health of the Russian Federation No. 173n dated March 29, 2019 «On approval of the procedure for conducting dispensary supervision of adults». (In Russ.)@@ Приказ Министерства здравоохранения РФ от 29 марта 2019 г. № 173н «Об утверждении порядка проведения диспансерного наблюдения за взрослыми». (In Russ.)
44. Drapkina O. M., Drozdova L. Y., Avdeev S. N. et al. The outpatient medical care in patients with chronic diseases under dispensary supervision in the conditions of the COVID-19 pandemic. Temporary guidelines. Version 2. Cardiovascular Therapy and Prevention. 2021;20(8): 3172. (In Russ.) doi: 10.15829/1728-8800-2021-3172.@@ Драпкина О. М., Дроздова Л. Ю., Авдеев С. Н. и др. Оказание амбулаторно-поликлинической медицинской помощи пациентам с хроническими заболеваниями, подлежащим диспансерному наблюдению, в условиях пандемии COVID-19. Временные методические рекомендации. Версия 2. Кардиоваскулярная терапия и профилактика. 2021;20(8):3172. (In Russ.) doi: 10.15829/1728-8800-2021-3172.
Review
For citations:
Livzan M.A., Gaus O.V., Lisovskiy M.A., Mozgovoi S.I., Rubtsov V.A., Parygina M.N. Clinical supervision of chronic atrophic gastritis. Experimental and Clinical Gastroenterology. 2023;(3):148-155. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-211-3-148-155
Views:
1629
Email this article 